Gut bugs and blood clues may guide pancreatic cancer therapy

NCT ID NCT07036978

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to find biological markers in the blood, immune system, and gut microbiome that can help doctors choose the best treatment for people with advanced pancreatic cancer that cannot be removed by surgery. Researchers will collect blood and stool samples from 140 participants in Taiwan and track their response to standard therapy. The goal is to create a personalized treatment plan based on each person's unique profile, potentially improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Linkou Chang Gung Memorial Hospital

    Taoyuan, 333, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.